Drilldown: Medicines
Use the filters below to narrow your results.
generic:
brand:
classes:
mechanism:
None (1) ·
Humanized IgG1 monoclonal antibody binding CGRP peptide; IV infusion enables fastest onset of any CGRP mAb (1) ·
Humanized IgG4 monoclonal antibody binding CGRP peptide; prevents CGRP from activating its receptor (1) ·
Non-selective competitive antagonist at β1 and β2 adrenergic receptors. Lipophilic; significant blood–brain barrier penetration, accounting for its CNS effects. (1)
uses:
Preventive treatment of migraine in adults (1) ·
Preventive treatment of migraine in adults; episodic cluster headache (1) ·
'"`UNIQ--vote-00000015-QINU`"', '"`UNIQ--vote-00000016-QINU`"' (1) ·
'"`UNIQ--vote-000005E7-QINU`"', '"`UNIQ--vote-000005E8-QINU`"', '"`UNIQ--vote-000005E9-QINU`"', '"`UNIQ--vote-000005EA-QINU`"', '"`UNIQ--vote-000005EB-QINU`"' (1)
starting dose:
100 mg IV every 3 months; may increase to 300 mg IV every 3 months (1) ·
10–40 mg (situational anxiety); 40 mg BID (HTN) (1) ·
Migraine: 240 mg SC loading dose, then 120 mg SC monthly. Cluster: 300 mg SC at onset of cluster period, then monthly during cluster. (1) ·
Oral: 1500 mg PO QID for 2-3 days (load), then 750-1500 mg QID maintenance. IV/IM: 1000 mg every 8 hours for acute spasm (1)
preparations:
fda max:
routes:
onset:
duration:
halflife: (Click arrow to add another value)
bioavailability:
pregnancy:
Error in "where" parameter: the string "--" cannot be used within #cargo_query.
There are no results for this report.